Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.

Icli, F.Altundag, K.Coskun, U.Paydas, S.Basaran, G.Saip, P.Dogu, G. G.2024-04-242024-04-2420110732-183X1527-7755https://doi.org/10.1200/jco.2011.29.15_suppl.629https://hdl.handle.net/11468/18272[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.Conference Object2915WOS:00020888030013210.1200/jco.2011.29.15_suppl.629Q1